Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02813980 · ClinicalTrials.gov registry record
Neural Circulatory Control and SUDEP Risk.
A clinical trial of Epilepsy and Seizures, sponsored by Mayo Clinic.
- Active
- Registry status
- 39
- Enrollment target
- 1
- Study location
NCT02813980 is a study of Epilepsy and Seizures that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 39 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02813980, a study of Epilepsy and Seizures, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators believe epilepsy alters the way the body controls blood pressure, heart rate and breathing, and these changes increase the risk of sudden unexpected death in patients with epilepsy (SUDEP). SUDEP-7 is a risk scoring tool which may correlate with these changes to the heart and blood vessels. This research study measures those differences which may help identify new markers to help predict those patients at greatest risk in the future.
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2016-06 |
| Est. Completion | 2030-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02813980
The ClinicalTrials.gov registry entry for NCT02813980 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (96% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Epilepsy appearing as the primary indexed condition, and to 0 interventions.
NCT02813980 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT02813980 about?
NCT02813980 is a clinical study titled "Neural Circulatory Control and SUDEP Risk.". The investigators believe epilepsy alters the way the body controls blood pressure, heart rate and breathing, and these changes increase the risk of sudden unexpected death in patients with epilepsy (SUDEP). SUDEP-7 is a risk scoring tool which may correlate with these changes to the heart and blood...
What is the current status of trial NCT02813980?
This trial is currently active not recruiting. The enrollment target is 39 participants. The study started on 2016-06. Estimated completion is 2030-12.
What conditions does trial NCT02813980 study?
This clinical trial studies the following conditions: Epilepsy, Seizures.
Who is sponsoring clinical trial NCT02813980?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02813980 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes
RECRUITING
-
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
RECRUITING
-
SeizEAR Safety Study
RECRUITING · NA
-
Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding
RECRUITING
-
Tumor Related Epilepsy
RECRUITING
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.